{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-041896","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2021-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.105581+00:00","generated_at":"2026-06-29T20:39:04.682957+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Imara Q2 net loss $13.2M; IMR-687 SCD trial fully enrolled; interim data Q4 2021","bullets":["Net loss $13.2M ($0.74/share) vs $10.2M ($0.59) in Q2 2020.","Cash $66.8M at June 30; $50M July offering extends runway through 2022.","SCD Phase 2b (Ardent) enrollment complete; primary analysis Q1 2022, interim Q4 2021.","Beta-thalassemia Phase 2b (Forte) TDT cohort fully enrolled; interim data Q4 2021; NTDT half enrolled.","Developing HFpEF Phase 2 protocol; FDA interaction planned Q4 2021; Laura Williams appointed to board."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-041896","json":"https://secwatch.observer/filing/0001564590-21-041896.json","markdown":"https://secwatch.observer/filing/0001564590-21-041896.md","text":"https://secwatch.observer/filing/0001564590-21-041896.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000156459021041896/0001564590-21-041896-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000156459021041896/imra-8k_20210630.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T20:39:04.682957+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}